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Background and study objective: Several
studies suggest a protective role of green
tea catechins against prostate cancer (PCa). In order to evalu-
ate the efficacy of green tea catechins for chemoprevention of
PCa in patients with high-grade prostate intraepithelial neo-
plasia (HG-PIN) we performed a phase II clinical trial. 
Methods: Sixty volunteers with HG-PIN were enrolled to carry
out a double-blind randomized placebo-controlled phase II
clinical trial. Treated group took daily 600 mg of green tea
catechins (Categ Plus®) for 1 year. Patients were screened at 6
and 12 months through prostatic biopsy and measurements of
prostate-specific antigen (PSA). 
Results: Despite the statistically significant reduction of PSA
observed in subjects who received green tea catechins for 6
and 12 months, we did not find any statistical difference in
PCa incidence between the experimental groups neither after 6
nor after 12 months. However, throughout the one-year fol-
low-up we observed very limited adverse effects induced by
green tea catechins and a not significant improvement in lower
urinary tract symptoms and quality of life. 
Conclusions: Although the small number of patients enrolled in
our study and the relatively short duration of intervention, our
findings seems to deny the efficacy of green tea catechins.
However, results of our clinical study, mainly for its low statis-
tical strength, suggest that the effectiveness of green tea cate-
chins should be evaluated in both a larger cohort of men and
longer trial.
KEY WORDS: Prostate cancer; Green tea catechins; High-grade
intra-epithelial neoplasia (HG-PIN); Herbal medicines; PSA;
Complementary therapies.
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usually, requires more than two decades for its develop-
ment. Thus, it can be considered as an important chance
for early prediction or chemoprevention through thera-
peutic or nutritional interventions, especially in the case
of pre-malignant lesions such as high-grade prostate
intraepithelial neoplasia (HG-PIN) (1). A chemopreven-
tion approach in patients with high risk of PCa can be
proposed in order to reduce the disease progression rate. 
It is known that natural product can be used to prevent
and/or alleviate several health disorders (2-4), including
those affecting the urinary tract (5). Moreover, regular
dietary habits coupled with a healthy lifestyle may pro-
tect against certain types of cancer (6, 7), including PCa.
In particular, epidemiological studies have shown that
Asiatic populations have lower rates of PCa compared to
others races and that Asian men who adopt a lifestyle
typical of Western countries because of migration to the
United States, have a significantly higher risk of PCa
when compared to their native Asian counterparts (8).
These findings strengthen the hypothesis that environ-
mental factors may contribute to PCa development and
that the use of dietary agents such as green tea may be an
important way to prevent or slow down the process of
carcinogenesis, hence the growing interest toward both
dietary supplements and complementary and alternative
medicine. In such context, diet-derived polyphenols
have received great attention among nutritionists, food
scientists, and consumers for their health-promoting
effects, including their use in the chemoprevention of
PCa (9), because oxidative stress has been implicated in
the aetiopathogenesis of PCa (10). Regardless, unre-
solved issues still linger.
Tea is the most consumed beverage worldwide, second
only to water in terms of popularity. It is prepared by
infusion of the Camelia sinensis L. (Theaceae) leaves. 
On the basis of both the differences in the processing
methods and chemical composition, it could be classi-
fied in three main types, the green tea (unfermented), the
oolong tea (partially fermented) and the black tea (fully
fermented). Habitual green tea consumption has long
been associated with preventive effects against chronic
pathologies including both heart and neurodegenerative
disease and cancer. In the latter field, several in vitro and
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INTRODUCTION
Prostate cancer (PCa) is a leading cause of cancer related
death among men in Western countries, representing a
major public health problem with high economic and
social costs. However, it is typically diagnosed in men
over 50 years of age and, as clinically significant PCa,
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in vivo studies showed that tea and its bioactive mole-
cules might modify the incidence and the progression of
PCa through their antioxidant properties and the ability
to interact with specific intracellular targets in cancerous
cells (11). 
The beneficial effects of green tea are attributed especial-
ly to its water soluble polyphenolic flavonoids, known as
catechins, including epicatechin (EC), epigallocatechin
(EGC), epicatechin-3-gallate (ECG) and the major
flavonoid (−)-epigallocatechin-3-gallate (EGCG). 
Their content is 30-40% of dry green tea weight, and
EGCG may represent up to 50% of the catechins by
weight. However, other polyphenols present in green tea
are quercetin, myricitrin and kaempferol. 
Bettuzzi et al. (12) proposed the green tea catechins as
chemopreventive agents against prostate cancer in men
with HG-PIN, confirming this suggestion in a long term
follow up study (13). However, others studies (14) often
report conflicting results, suggesting that habitual green
tea consumption may not provide the alleged protection
against cancer. Therefore, the aim of the study was to eval-
uate the efficacy of green tea catechins for chemopreven-
tion of PCa in patients with HG-PIN by a double-blind
randomized placebo-controlled phase II clinical trial.
METHODS
Study design
Sixty volunteers with HG-PIN were enrolled to carry out
a double-blind randomized placebo-controlled phase II
clinical trial in order to investigate whether green tea cat-
echins could prevent the occurrence of PCa in men at
high-risk. 
Ethics approval and consent to participate
This study was approved by the Modena Ethic Committee
(Italy) on 2007-04-10 (number 23/07) and carried out in
the Modena University Hospital (Italy) from May 2007 to
February 2011. The recommendations of the Declaration
of Helsinki and the guidelines of the International
Conference on Harmonization Good Clinical Practice were
observed. All volunteers have been properly informed
about the clinical trial and signed a free informed con-
sent form.
Study objectives. The primary objective was to deter-
mine the efficacy of green tea catechins for chemopre-
vention of PCa in patients with HG-PIN. Therefore, the
first goal of our study was to point out PCa incidence
during the 1-year study in the two arms. Moreover, dur-
ing the whole study, we recorded possible changes in
total serum prostate-specific antigen (PSA) values (sec-
ondary objective), together with the toxicity evaluation
as well as the patient’s lower urinary tract symptoms
(LUTS) and quality of life (QoL) scores assessments by
questionnaires. Subjects who were detected PCa during
the clinical trial were excluded from the study and sub-
jected to chemotherapy.
Study population. Eligibility criteria for enrolment
included: Caucasian men aged between 55 to 65 years
old with HG-PIN, as assessed by prostate biopsy. All vol-
unteers were properly advised about the clinical trial and
signed a free informed consent form. Exclusion criteria
included: men aged > 65 years, previous malignancies,
cancer diagnosis, antiandrogenic or chemoprevention
therapies, obesity, diabetes or other endocrinologic dis-
eases. The subjects enrolled in the trial were instructed
to abstain from green tea and its derivatives, antioxidants
or nutritional supplements and herbal therapies. 
Study procedures
During the initial visit, volunteers underwent an inter-
view to obtain medical history as well as a brief physical
assessment including a digital rectal examination.
Moreover, blood samples were collected for complete
blood count and serum PSA levels. Finally, baseline
assessments of LUTS and QoL, were obtained.
Upon determination of eligibility, a total of 60 patients
participating to the clinical trial were randomized (1:1) to
receive daily green tea catechins 600 mg (2 tablets of 300
mg of Categ Plus®, Sofar S.P.A, Milan, Italy) or placebo for
1 year. The random allocation sequence was obtained by
means of “Easy Random Picker” software (TrustFm© 1998-
2016). Both participants and care providers were blinded
after assignment to interventions, in order to avoid any
bias. Two capsules of Categ Plus® or placebo per day were
given to all subjects by the clinical trial investigators,
according to the double blind method. 
Follow up was carried out at 6 and 12 months with tox-
icity assessment (side effects), LUTS and QoL evaluation,
medical examination, rectal inspection, serum PSA levels
and prostate biopsy. PSA measurements as well as
immunohistochemistry evaluation of prostatic biopsies
were performed in the same hospital’s central laboratory
where was carried out the clinical trial (Modena
University Hospital, Italy). Possible changes in LUTS,
using the International Prostate Symptom Score (IPSS),
and QoL were evaluated as described (15, 16).
Statistical analysis
Statistical analyses of results were performed using the
Student’s t test. P-values < 0.05 were considered statisti-
cally significant. 
RESULTS
First, we have ensured that the randomization of volun-
teers in the two arms of the clinical trial had resulted in
two homogeneous groups with one another. A Consort
flow diagram of the study is shown in Figure 1. In particu-
lar, at the time of enrollment the age of subject, their
weight, the PSA value and the prostate volume were
recorded and statistically analyzed. In Table 1 are report-
ed their mean values. None of the variables considered
were significantly different in the two arms (age, p = 0.8;
PSA value, p = 0.16; prostate volume, p = 0.23). The two
groups were statistically analyzed to ensure homogeneity
between the two groups by the t test of Student (age, p =
0.580; PSA value, p = 0.790; prostate volume, p = 0.738).
Among the 60 patients that entered the study, 44 sub-
jects completed the study (22 cases and 22 controls)
with a drop out of 26.7%, whereas minimal side effects
were recorded. Indeed, although the majority of patients
tolerated the green tea relatively well, 8 patients with-
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drew from the clinical study because one selves’ deci-
sion. When toxicity did occur, it was of Grade 1 or 2,
including the following symptoms: nausea, emesis,
abdominal pain, insomnia, fatigue and diarrhea. 
Figure 2A shows that the incidence of new diagnoses of
PCa at 6 months was 9% (2/22) in the green tea cate-
chins-treated arm, and 18.1% (4/22) in the placebo
group; although these values are the one of the other
half, the difference between green tea-treated and place-
bo groups has not reached the statistical significance
(p = 0.5). Moreover, at 12 months follow up, two more
cases of PCa were diagnosed in the green tea catechins
group, reaching a 18% of PCa incidence also in the treat-
ed arm (Figure 2B). 
In the green tea catechins group we observed a progres-
sive reduction of the PSA value throughout the 1-year
study, as well as we found a deceleration of the PSA rise
in the green tea catechins group with respect to the
placebo ones, however without reaching statistical sig-
nificance (Table 2). Interestingly, after 12 months of
treatment we found a significant reduction of PSA values
in the green tea catechins group with respect to the
placebo ones (3.85 ± 1.8 ng/dl and 5.83 ± 2.65, respec-
tively; p < 0.05; Table 2). 
Finally, a certain improvement in LUTS and QoL scores
was found by analyzing the patient’s questionnaires filled
by the subjects belonging to green tea catechins group
throughout the 1-year study. However, no significant
differences between the treatment and placebo arms
were observed from baseline to end of study (data not
shown). 
DISCUSSION
PCa is considered the most common malignancy and the
second leading cause of cancer death among men in
United States and Europe. During its progression, cell
phenotype changes from normal to severe dysplasia
(high-grade prostatic intraepithelial neoplasia), to early
(superficial) cancers, and finally to metastatic disease.
The occurrence of latent PCa is consistently distributed,
suggesting that external issues such as diet, physical
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Table 1. 
Patient characteristics at the time of enrollment
(mean ± SD).
Mean Weight Prostate PSA
age (kg) volume (ml) value
Total population 
enrolled 64.34 ± 8.4 82.77 ± 6.6 44.74 ± 16 5.31 ± 2.5
Placebo arm 64.4 ± 8.9 80.9 ± 6.4 42.15 ± 15 4.7 ± 2.5
Green tea 
catechins-
treated arm 64.27 ± 8 84.64 ± 6 46.,87 ± 17.8 5.95 ± 2.3
Table 2. 
PSA values (ng/ml) throughout the 1-year study 
(mean ± SD).
Green tea Placebo P 
catechins-treated arm group value
Time of enrolment 5.9 ± 2.3 4.7 ± 2.5
6 months 4.9 ± 1.9 5.2 ± 2.1 N.S.
12 months 3.8 ± 1.8 5.8 ± 2.6 < 0.05
Figure 1. 
Consort flow diagram.
Figure 2. 
Incidence of new diagnosis of PCa at 6 (A) and 12 (B) months’ follow up.
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activity, and other lifestyle factors may be important in
the evolution into aggressive clinical diseases (17).
HG-PIN is a premalignant condition, defined by neo-
plastic development of epithelial cells among pre-exist-
ing benign prostatic acini or ducts, appearing as a sort of
intermediate stage between benign epithelium and
malignant carcinoma. Histologically, the main difference
with the prostate carcinoma is the conservation of the
basement membrane, which orients pathologists in indi-
cating an HG-PIN. On the other hand, cellular parame-
ters can be mismatched with a carcinoma, like the
prominent and abnormal nuclei, that are also character-
istic in HG-PIN (18). The incidence of HG-PIN on pro-
static biopsy averages approximately 15%, increasing
with patient’s age. Moreover, some areas of HG-PIN are
frequently found around prostatic cancerous lesions and
evolution into carcinoma is estimated in about 30% of
cases (19). Recent literature states that 30% of men with
HG-PIN would develop prostate cancer within 1 year
after repeated biopsy (1). In this contest, the chemopre-
vention (the administration of agents to prevent the
induction or to delay the progression of cancers) play an
important role, trying to stop multistage carcinogenesis
before its development in malignancy. PCa with its high
prevalence and long latency provides a promising
approach for evaluating agents for chemoprevention.
It is known that the possible protective action of green
tea on PCa is due to the presence of catechins, above all
EGCG, since black tea, poor of these compounds, does
not play a role in prevention from PCa (20). An impor-
tant clinical trial investigating the effectiveness of green
tea catechins on PCa was carried out by Bettuzzi et al.
(12), suggesting that green tea polyphenols may be effec-
tive for treating premalignant lesions before PCa devel-
ops. In this prospective, randomized, double-blind,
placebo-controlled clinical trial, 60 volunteers with HG-
PIN received orally 600 mg per day of green tea cate-
chins or placebo for one year, and were subjected to
medical examinations and prostate biopsies at 6 at 12
months. Authors concluded that green tea catechins
might provide a 90% of chemoprevention efficacy.
Following the same HG-PIN cohort of subject for two
years (despite a considerable dropout rate), the reduc-
tion of PCa incidence in the green tea catechins arm still
remained significant, thus suggesting a long lasting inhi-
bition of cancer development achieved with one-year
therapy (13).
In our study, we failed to confirm a clear association
between green tea catechins and PCa chemoprevention,
suggesting that the lack of effectiveness we described
could be due to the somewhat small number of enrolled
volunteers as well as to limited length of the study.
However, results of our clinical trial are consistent with
studies supporting the notion that green tea intake does
not protect against prostate cancer. For instance, a
prospective cohort study performed using data from a
follow-up database of 27.293 of Singapore Chinese men,
concluded that there was no association between daily
green tea intake and prostate cancer risk, compared with
no green tea intake (21). Moreover, results of a prospec-
tive cohort study that involved 19.561 Japanese men
from Ohsaki to whom was self-administered a question-
naire suggested that green-tea intake did not reduce PCa
(22). On the contrary, a case-control study in China
found that green-tea intake was associated with a lower
risk of prostate cancer (23), whereas a case-control study
in Japan showed a modest reduction in PCa (24). 
Borderline results were obtained also in a randomized,
double-blind, placebo-controlled trial performed in men
with PCa scheduled to undergo radical prostatectomy
that received daily either a drug containing 800 mg green
tea catechins or placebo for 3 to 6 weeks before surgery.
Results of the study indicate that the treatment with
green tea catechins resulted in favorable but not statisti-
cally significant changes in serum PSA as well as the pro-
portion of subjects who had a decrease in Gleason score
between biopsy and surgical specimens (25). A phase II
trial aimed to estimate percentage of patients with andro-
gen independent metastatic PCa who sustained a decline
in PSA level with green tea, showed its limited capabili-
ty to breakdown PSA, although no patient manifested a
tumor response during the months of treatment (26).
Another prospective clinical trial for hormone refractory
prostate cancer indicated minimal clinical activity of
green tea extract capsules in 15 men (27). Finally, a
meta-analysis indicated that consumption of green tea
may have a protective effect on PCa in Asian popula-
tions, suggesting that further prospective cohort studies
are needed to obtain a definitive conclusion in this field,
especially with regard to the protective role of green tea
on PCa across different regions apart from Asia (20).
It is known that inflammation plays an important role in
the aetiology of prostate cancer (28). On the other hand,
several in vitro and in vivo studies have shown that both
green tea and their catechins may inhibit carcinogenesis
during the initiation, promotion and progression stages
through many mechanisms, including the antioxidant
effects (29). Moreover, Mukherjee et al. (30) reported that
EGCG suppresses inflammation in prostate cancer cells,
thus reducing the risk of PCa. Therefore, we speculate
that the significant reduction of PSA values throughout
the one-year study, as well as the not significant decrease
of PCa at the 6 month follow up, we observed in our
study, could be linked to the anti-inflammatory proper-
ty of green tea. This hypothesis was also supported by a
recent open label, phase II clinical trial carried out in 113
men diagnosed with prostate cancer randomized who
received six cups daily of brewed green tea or brown tea
or water for three to eight weeks prior to radical prosta-
tectomy (31). In prostate tissue, Henning et al. found that
green tea consumption led to a significant decrease in
nuclear immunostaining of nuclear factor kappa B
(NFκB) compared to water control, which may reduce
inflammatory processes that may contribute to prostate
cancerogenesis. Moreover, evidences of both systemic
antioxidant effect (reduced urinary 8-hydroxy-
deoxyguanosine) and small but statistically significant
decrease in PSA levels were observed. LUTS are a com-
plex of obstructive (intermittency flow issue, incomplete
voiding, weak urinary stream) and irritative (pollakiuria
nocturia, urgency and burning during urination) symp-
toms that affect the quality of life and are quite common
in men over the age of 60 years and in those with benign
prostatic hyperplasia (32). Interestingly, the analysis of
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questionnaires administered to subjects participating in
the clinical study showed a small but not significant
improvement of LUTS or QoL scores in the green tea-
treated group respect to the control one. This finding
supports the hypothesis that the anti-inflammatory effect
of green tea catechins both can determine the reduction
in blood levels of PSA and can relieve the symptoms of
LUTS, thus enhancing the quality of life.
CONCLUSIONS
In recent decades, natural drugs gained particular atten-
tion mainly because of their antioxidant and anti-inflam-
matory activities exploitable in the prevention of certain
chronic degenerative pathologies (4, 33-35). However,
the increased employment of alternative and comple-
mentary medicines requires a lot of attention from the
scientific community in order to evaluate the effective-
ness and safety of herbal preparations since studies have
cast some doubts on whether their use is really produc-
ing an alternative to synthetic drugs (5, 36, 37). 
Although numerous in vitro and in vivo studies have sug-
gested a protective effect of green-tea polyphenols
against development of prostate cancer, to date this has
not been unequivocally demonstrated in humans.
Despite the small number of patients we enrolled and the
relatively short duration of intervention, results of our
clinical trial indicate that green tea catechins do not
reduce the chance of a later development of PCa in men
with HGPIN. However, the minor incidence of new diag-
noses of PCa at 6 months follow-up (albeit not statisti-
cally significant) and the significant reduction of PSA lev-
els at both 6 and 12 months follow-up, associated to the
quite favourable trend that we observed in our clinical
trial (very limited adverse effects and improvement in
LUTS and quality of life) suggest that future studies with
a larger cohort of men and longer durations of interven-
tions are warranted. Moreover, the results of our trial
provide a glimpse of the possibility that the green tea cat-
echins might be useful, alone or in combination with
other drugs, for the prevention or treatment of other pro-
static pathologies.
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